Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau.

Rousseaux MW, de Haro M, Lasagna-Reeves CA, De Maio A, Park J, Jafar-Nejad P, Al-Ramahi I, Sharma A, See L, Lu N, Vilanova-Velez L, Klisch TJ, Westbrook TF, Troncoso JC, Botas J, Zoghbi HY.

Elife. 2016 Oct 25;5. pii: e19809. doi: 10.7554/eLife.19809.

2.

The effect of MAPT haplotype on neocortical Lewy body pathology in Parkinson disease.

Robakis D, Cortes E, Clark LN, Vonsattel JP, Virmani T, Alcalay RN, Crary JF, Levy OA.

J Neural Transm (Vienna). 2016 Jun;123(6):583-8. doi: 10.1007/s00702-016-1552-3.

PMID:
27098667
3.

Parkinson disease and progressive supranuclear palsy: protein expression in skin.

Rodríguez-Leyva I, Chi-Ahumada EG, Carrizales J, Rodríguez-Violante M, Velázquez-Osuna S, Medina-Mier V, Martel-Gallegos MG, Zarazúa S, Enríquez-Macías L, Castro A, Calderón-Garcidueñas AL, Jiménez-Capdeville ME.

Ann Clin Transl Neurol. 2016 Feb 1;3(3):191-9. doi: 10.1002/acn3.285.

4.
5.

Lack of Neuronal IFN-β-IFNAR Causes Lewy Body- and Parkinson's Disease-like Dementia.

Ejlerskov P, Hultberg JG, Wang J, Carlsson R, Ambjørn M, Kuss M, Liu Y, Porcu G, Kolkova K, Friis Rundsten C, Ruscher K, Pakkenberg B, Goldmann T, Loreth D, Prinz M, Rubinsztein DC, Issazadeh-Navikas S.

Cell. 2015 Oct 8;163(2):324-39. doi: 10.1016/j.cell.2015.08.069.

6.

The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration.

Deger JM, Gerson JE, Kayed R.

Aging Cell. 2015 Oct;14(5):715-24. doi: 10.1111/acel.12359. Review.

7.

Biomarkers in biological fluids for dementia with Lewy bodies.

Schade S, Mollenhauer B.

Alzheimers Res Ther. 2014 Oct 16;6(5-8):72. doi: 10.1186/s13195-014-0072-3. Review.

8.

Caenorhabditis elegans: a model to investigate oxidative stress and metal dyshomeostasis in Parkinson's disease.

Chege PM, McColl G.

Front Aging Neurosci. 2014 May 19;6:89. doi: 10.3389/fnagi.2014.00089. Review.

9.

What can biomarkers tell us about cognition in Parkinson's disease?

Mollenhauer B, Rochester L, Chen-Plotkin A, Brooks D.

Mov Disord. 2014 Apr 15;29(5):622-33. doi: 10.1002/mds.25846. Review.

10.

Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease.

Roy B, Jackson GR.

Hum Mol Genet. 2014 Jun 1;23(11):3008-23. doi: 10.1093/hmg/ddu011.

11.

Genetic susceptibility loci, environmental exposures, and Parkinson's disease: a case-control study of gene-environment interactions.

Chung SJ, Armasu SM, Anderson KJ, Biernacka JM, Lesnick TG, Rider DN, Cunningham JM, Ahlskog JE, Frigerio R, Maraganore DM.

Parkinsonism Relat Disord. 2013 Jun;19(6):595-9. doi: 10.1016/j.parkreldis.2013.02.008.

12.
13.

Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo.

Wu J, Lou H, Alerte TN, Stachowski EK, Chen J, Singleton AB, Hamilton RL, Perez RG.

Neuroscience. 2012 Apr 5;207:288-97. doi: 10.1016/j.neuroscience.2012.01.028.

14.

Postmortem studies in Parkinson's disease.

Hartmann A.

Dialogues Clin Neurosci. 2004 Sep;6(3):281-93.

15.

Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility?

Biernacka JM, Armasu SM, Cunningham JM, Ahlskog JE, Chung SJ, Maraganore DM.

Parkinsonism Relat Disord. 2011 Dec;17(10):730-6. doi: 10.1016/j.parkreldis.2011.07.001.

16.

A tangled web - tau and sporadic Parkinson's disease.

Wray S, Lewis PA.

Front Psychiatry. 2010 Dec 27;1:150. doi: 10.3389/fpsyt.2010.00150.

18.

Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.

Duka T, Duka V, Joyce JN, Sidhu A.

FASEB J. 2009 Sep;23(9):2820-30. doi: 10.1096/fj.08-120410.

19.

Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum.

Pattarini R, Rong Y, Qu C, Morgan JI.

Neuroscience. 2008 Sep 9;155(4):1174-94. doi: 10.1016/j.neuroscience.2008.06.064.

20.

Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study.

Tobin JE, Latourelle JC, Lew MF, Klein C, Suchowersky O, Shill HA, Golbe LI, Mark MH, Growdon JH, Wooten GF, Racette BA, Perlmutter JS, Watts R, Guttman M, Baker KB, Goldwurm S, Pezzoli G, Singer C, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Laramie JM, DeStefano AL, Litvan I, Nicholson G, Corbett A, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Sherman S, Al-hinti J, Drasby E, Nance M, Moller AT, Ostergaard K, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH.

Neurology. 2008 Jul 1;71(1):28-34. doi: 10.1212/01.wnl.0000304051.01650.23.

Supplemental Content

Support Center